MAPT and myeloid sarcoma: Both subgroups of MS patients (treated patients and untreated ones) had significantly elevated intrathecal synthesis of anti-tau antibodies compared to control patients (treated patients vs. controls p<0.001; untreated patients vs. controls p<0.001) (Fig. 3B).